RU2299889C2 - Конформационно аномальные формы белков тау и специфические антитела к ним - Google Patents
Конформационно аномальные формы белков тау и специфические антитела к ним Download PDFInfo
- Publication number
- RU2299889C2 RU2299889C2 RU2003126594/13A RU2003126594A RU2299889C2 RU 2299889 C2 RU2299889 C2 RU 2299889C2 RU 2003126594/13 A RU2003126594/13 A RU 2003126594/13A RU 2003126594 A RU2003126594 A RU 2003126594A RU 2299889 C2 RU2299889 C2 RU 2299889C2
- Authority
- RU
- Russia
- Prior art keywords
- tau protein
- human tau
- antibody
- tau
- amino acid
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0017501A AT500379B8 (de) | 2001-02-02 | 2001-02-02 | Tau-proteine |
| ATA175/2001 | 2001-02-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003126594A RU2003126594A (ru) | 2005-03-10 |
| RU2299889C2 true RU2299889C2 (ru) | 2007-05-27 |
Family
ID=3658236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003126594/13A RU2299889C2 (ru) | 2001-02-02 | 2002-01-29 | Конформационно аномальные формы белков тау и специфические антитела к ним |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7446180B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1355949B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4163955B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101307107A (cg-RX-API-DMAC7.html) |
| AT (2) | AT500379B8 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002237296A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2437453C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60235746D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1355949T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2339427T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2299889C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002062851A1 (cg-RX-API-DMAC7.html) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2639537C2 (ru) * | 2011-10-07 | 2017-12-21 | Ац Иммуне С.А. | Фосфоспецифичные антитела, распознающие тау |
| US10633436B2 (en) | 2015-06-05 | 2020-04-28 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| US10836817B2 (en) | 2016-12-07 | 2020-11-17 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
| RU2743152C2 (ru) * | 2014-06-27 | 2021-02-15 | Си2Эн ДАЙАГНОСТИКС ЭлЭлСи | Гуманизированные анти-тау-антитела |
| RU2760875C1 (ru) * | 2016-07-12 | 2021-12-01 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
| US11427629B2 (en) | 2016-12-07 | 2022-08-30 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
| RU2808829C2 (ru) * | 2019-03-18 | 2023-12-05 | Регенерон Фармасьютикалз, Инк. | Платформа crispr/cas для исключающего скрининга для выявления генетических уязвимостей, связанных с агрегацией тау-белка |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| WO2004007722A2 (en) * | 2002-07-12 | 2004-01-22 | Axon Neuroscience Forschungs- Und Entwicklungs Gmbh | Transgenic animal expressing alzheimer’s tau protein |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| ES2321996B1 (es) * | 2006-01-26 | 2010-03-05 | Consejo Superior Investig. Cientificas | Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias. |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| WO2009143556A1 (en) * | 2008-05-30 | 2009-12-03 | The University Of Sydney | TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION |
| EP4218794A3 (en) * | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP2470211B1 (en) * | 2009-08-28 | 2016-01-27 | The Board of Regents of The University of Texas System | Antibodies that bind tau oligomers |
| US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| ITRM20100320A1 (it) | 2010-06-11 | 2011-12-11 | Consiglio Nazionale Ricerche | Metodo per la diagnostica e il trattamento delle taupatie |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| LT2627672T (lt) | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Žmogaus antikūnai prieš tau baltymą |
| CA2817973C (en) | 2010-10-15 | 2019-06-25 | The Board Of Regents Of The University Of Texas System | Antibodies that bind amyloid oligomers |
| WO2012106363A2 (en) | 2011-01-31 | 2012-08-09 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| WO2012162179A1 (en) * | 2011-05-20 | 2012-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
| EP3275461A1 (en) * | 2011-09-19 | 2018-01-31 | Axon Neuroscience SE | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field |
| EP2870176A4 (en) | 2012-07-03 | 2016-09-28 | Univ Washington | ANTIBODIES DIRECTED AGAINST TAU |
| EP2885010B1 (en) | 2012-08-16 | 2020-01-01 | Ipierian, Inc. | Methods of treating a tauopathy |
| US9200068B2 (en) * | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| JP6284548B2 (ja) | 2012-12-21 | 2018-02-28 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | ヒト抗タウ抗体 |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
| MX374811B (es) * | 2013-03-15 | 2025-03-06 | Ac Immune Sa | Anticuerpos anti-tau y métodos de uso. |
| CR20160270A (es) | 2013-12-20 | 2016-09-05 | Hoffmann La Roche | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN |
| CN105939722A (zh) | 2014-02-14 | 2016-09-14 | 伊皮埃里安股份有限公司 | Tau肽,抗Tau抗体,及其使用方法 |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| EP3166688B1 (en) | 2014-07-08 | 2024-08-21 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
| AR103713A1 (es) | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
| ES2809728T3 (es) | 2015-06-24 | 2021-03-05 | Hoffmann La Roche | Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso |
| SG10202010735PA (en) | 2015-07-06 | 2020-11-27 | UCB Biopharma SRL | Tau-binding antibodies |
| US10988528B2 (en) | 2015-08-13 | 2021-04-27 | New York University | Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| MX2018013384A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| JP6949102B2 (ja) | 2016-08-09 | 2021-10-13 | イーライ リリー アンド カンパニー | 併用療法 |
| SG11201910066QA (en) | 2017-05-02 | 2019-11-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| CN107686839B (zh) * | 2017-09-25 | 2020-12-04 | 安徽朵能生物科技有限公司 | 微管结合蛋白cript、其治疗性突变体及其应用 |
| EP3829634A1 (en) | 2018-07-31 | 2021-06-09 | Eli Lilly and Company | Combination therapy |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| TWI859197B (zh) | 2019-03-03 | 2024-10-21 | 愛爾蘭商普羅帝納生物科學公司 | 識別tau之抗體 |
| EP4317950B1 (en) | 2019-03-18 | 2026-01-28 | Regeneron Pharmaceuticals, Inc. | Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation |
| CN113874078B (zh) | 2019-04-05 | 2025-05-06 | Tauc3生物制品有限公司 | 抗tauc3抗体及其应用 |
| GB2585252A (en) | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| US20240101654A1 (en) | 2020-12-29 | 2024-03-28 | Neurimmune Ag | Human anti-tau antibodies |
| WO2026102093A1 (en) | 2024-11-07 | 2026-05-15 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733734A (en) * | 1991-08-14 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments |
| JPH06239899A (ja) | 1993-02-12 | 1994-08-30 | Teijin Ltd | ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法 |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| US20020164657A1 (en) * | 2001-02-23 | 2002-11-07 | Sharma Satish K. | Assays for assessing A beta-Tau aggregation |
-
2001
- 2001-02-02 AT AT0017501A patent/AT500379B8/de not_active IP Right Cessation
-
2002
- 2002-01-29 DK DK02703586.4T patent/DK1355949T3/da active
- 2002-01-29 US US10/470,928 patent/US7446180B2/en not_active Expired - Lifetime
- 2002-01-29 ES ES02703586T patent/ES2339427T3/es not_active Expired - Lifetime
- 2002-01-29 EP EP02703586A patent/EP1355949B1/en not_active Expired - Lifetime
- 2002-01-29 DE DE60235746T patent/DE60235746D1/de not_active Expired - Lifetime
- 2002-01-29 CN CNA2008101081547A patent/CN101307107A/zh active Pending
- 2002-01-29 CA CA2437453A patent/CA2437453C/en not_active Expired - Lifetime
- 2002-01-29 JP JP2002563203A patent/JP4163955B2/ja not_active Expired - Lifetime
- 2002-01-29 RU RU2003126594/13A patent/RU2299889C2/ru active
- 2002-01-29 AU AU2002237296A patent/AU2002237296A1/en not_active Abandoned
- 2002-01-29 CN CNB028053133A patent/CN100503638C/zh not_active Expired - Lifetime
- 2002-01-29 AT AT02703586T patent/ATE461941T1/de active
- 2002-01-29 WO PCT/EP2002/000897 patent/WO2002062851A1/en not_active Ceased
-
2008
- 2008-11-04 US US12/264,694 patent/US20090123936A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| Acta virologica, 38, 1994, p.p.173-189, M.Novak. Truncated tau protein as new Marker for Alzheimer's disease. J. of Neuroscience Research, 55, 1999, p.p.713-723, Gregory A.Jicha et al. Sequence Requirements for Formation of Conformational Variants of Tau Similar to Those Found in Alzheimer's Desiese. Neurobiology of Aging, 21. 2000, p.p.719-727, Charles L. Weaver et al. Conformational change as one of the earliest alterations of tau in Alzheimer's disease. * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10066010B2 (en) | 2011-10-07 | 2018-09-04 | Ac Immune S.A. | Methods of diagnosing diseases caused by or associated with neurofibrillary tangles by phosphospecific antibodies recognising Tau |
| RU2639537C2 (ru) * | 2011-10-07 | 2017-12-21 | Ац Иммуне С.А. | Фосфоспецифичные антитела, распознающие тау |
| RU2743152C2 (ru) * | 2014-06-27 | 2021-02-15 | Си2Эн ДАЙАГНОСТИКС ЭлЭлСи | Гуманизированные анти-тау-антитела |
| US11555065B2 (en) | 2015-06-05 | 2023-01-17 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
| RU2732122C2 (ru) * | 2015-06-05 | 2020-09-11 | Дженентек, Инк. | Антитела против тау-белка и способы их применения |
| US10633436B2 (en) | 2015-06-05 | 2020-04-28 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| US12486319B2 (en) | 2015-06-05 | 2025-12-02 | Ac Immune Sa | Anti-tau antibodies and methods of use |
| RU2760875C1 (ru) * | 2016-07-12 | 2021-12-01 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
| US10836817B2 (en) | 2016-12-07 | 2020-11-17 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
| US11352419B2 (en) | 2016-12-07 | 2022-06-07 | Ac Immune Sa | Anti-tau antibodies and methods of use |
| US11427629B2 (en) | 2016-12-07 | 2022-08-30 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
| RU2808829C2 (ru) * | 2019-03-18 | 2023-12-05 | Регенерон Фармасьютикалз, Инк. | Платформа crispr/cas для исключающего скрининга для выявления генетических уязвимостей, связанных с агрегацией тау-белка |
| RU2819350C2 (ru) * | 2019-03-18 | 2024-05-17 | Регенерон Фармасьютикалз, Инк. | Скрининговая платформа crispr/cas для идентификации генетических модификаторов засева или агрегации тау-белка |
| RU2857374C2 (ru) * | 2019-03-18 | 2026-03-02 | Регенерон Фармасьютикалз, Инк. | Скрининговая платформа crispr/cas для идентификации генетических модификаторов засева или агрегации тау-белка |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1492879A (zh) | 2004-04-28 |
| ES2339427T3 (es) | 2010-05-20 |
| US20040082763A1 (en) | 2004-04-29 |
| EP1355949A1 (en) | 2003-10-29 |
| CN100503638C (zh) | 2009-06-24 |
| JP4163955B2 (ja) | 2008-10-08 |
| WO2002062851A8 (en) | 2002-09-12 |
| JP2004532817A (ja) | 2004-10-28 |
| CA2437453C (en) | 2013-06-11 |
| DK1355949T3 (da) | 2010-05-25 |
| CA2437453A1 (en) | 2002-08-15 |
| DE60235746D1 (de) | 2010-05-06 |
| CN101307107A (zh) | 2008-11-19 |
| AT500379A2 (de) | 2005-12-15 |
| ATE461941T1 (de) | 2010-04-15 |
| WO2002062851A1 (en) | 2002-08-15 |
| AT500379B8 (de) | 2009-08-15 |
| AT500379B1 (de) | 2009-07-15 |
| US20090123936A1 (en) | 2009-05-14 |
| AU2002237296A1 (en) | 2002-08-19 |
| EP1355949B1 (en) | 2010-03-24 |
| RU2003126594A (ru) | 2005-03-10 |
| US7446180B2 (en) | 2008-11-04 |
| AT500379A3 (de) | 2009-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2437453C (en) | Conformationally abnormal forms of tau proteins and specific antibodies thereto | |
| US10538581B2 (en) | Anti-Aβ globulomer 4D10 antibodies | |
| Mercken et al. | Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes | |
| CA2514582C (en) | Amyloid-.beta.(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof | |
| JP3909084B2 (ja) | 微小管結合タンパク質タウに対するモノクローナル抗体 | |
| KR101667623B1 (ko) | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 | |
| US20130236466A1 (en) | AMYLOID BETA-DERIVED DIFFUSIBLE LIGANDS (ADDLs), ADDL-SURROGATES, ADDL-BINDING MOLECULES, AND USES THEREOF | |
| JP2008513732A (ja) | アミロイドβ(Abeta)の病理学的なアセンブリを標的とするモノクローナル抗体 | |
| CN107531796A (zh) | 识别AChE的T14肽的抗体 | |
| Vechterova et al. | DC11: a novel monoclonal antibody revealing Alzheimer's disease-specific tau epitope | |
| JPWO2000057189A1 (ja) | メグシンタンパク質の検出方法およびその用途 | |
| JPH03151893A (ja) | アルツハイマー病に関与するモノクローナル抗体、これらのモノクローナル抗体を分泌するハイブリドーマ、これらの抗体により認識される抗原、及びそれらの適用 | |
| CN117589996A (zh) | 强毒性淀粉样蛋白寡聚体的诊断用途 | |
| DK2289909T3 (en) | The screening method, method of purification of non-diffusing alpha-beta oligomers selective antibodies to said non-diffunderingsdygtige alpha-beta oligomers and a method of producing said antibodies | |
| JP2000034300A (ja) | 抗リン酸化タウ蛋白質抗体及びそれを用いるアルツハイマー病の検出方法 | |
| AU2012201856A1 (en) | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies | |
| US20180284137A1 (en) | Diagnostic assay for alzheimer's disease | |
| US20170096476A1 (en) | Methods and compositions related to amyloid-beta-42 oligomers | |
| JP2005261244A (ja) | 腎糸球体上皮細胞局在タンパク質特異性抗体 | |
| MX2008007006A (es) | Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos | |
| JPH02291965A (ja) | アルツハイマー症の診断における非神経組織の検査法 |